Jonathan Zanger, Chief Technology Officer at Check Point, brings a rare combination of elite military intelligence experience, deep AI expertise, and operational leadership across both startups and ...
The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
They did not stumble into this. Every move was planned, every wallet pre-selected, every transfer timed to the second. As ...
Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced results from the Phase 3 LITESPARK-012 ...
Cash position of €17.2m as of December 31, 2025Progresses achieved with our flagship projects in 2025:Chinese partner Tonghua Dongbao completed BioChaperone® Lispro Phase 3 program with positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results